Standard BioTools Toekomstige groei

Future criteriumcontroles 1/6

De verwachting is dat Standard BioTools de winst en omzet met respectievelijk 8.1% en 16.4% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 4.8% per jaar.

Belangrijke informatie

8.1%

Groei van de winst

4.8%

Groei van de winst per aandeel

Life Sciences winstgroei	18.4%
Inkomstengroei	16.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	04 Jan 2024

Recente toekomstige groei-updates

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10

Recent updates

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

Dec 19

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Apr 17

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Apr 02

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Oct 14

Winst- en omzetgroeiprognoses

NasdaqGM:SLGC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	140	-69	N/A	-81	2
12/31/2025	118	-84	N/A	-87	2
12/31/2024	99	-100	N/A	-91	4
12/31/2023	84	-111	N/A	-113	4
9/30/2023	82	-130	-122	-117	N/A
6/30/2023	101	-141	-139	-134	N/A
3/31/2023	95	-139	-144	-138	N/A
12/31/2022	98	-109	-106	-101	N/A
9/30/2022	102	-83	-96	-92	N/A
6/30/2022	80	-92	-75	-70	N/A
3/31/2022	86	-82	-46	-42	N/A
12/31/2021	82	-88	-44	-40	N/A
9/30/2021	87	-73	-27	-23	N/A
6/30/2021	81	-39	-13	-11	N/A
3/31/2021	68	-45	-22	-21	N/A
12/31/2020	56	-53	-29	-28	N/A
12/31/2019	32	-57	-51	-51	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat SLGC de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat SLGC de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat SLGC de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van SLGC ( 16.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van SLGC ( 16.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SLGC naar verwachting over 3 jaar hoog zal zijn

Standard BioTools Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Consensus estimates of losses per share improve by 10%

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 21% to US$3.93

Recent updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Madryn Asset Management, LP Issues Presentation to SomaLogic Shareholders

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

Consensus estimates of losses per share improve by 10%

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 21% to US$3.93

Somalogic Announces New Somascan® 11K Platform

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Somalogic, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Less than half of directors are independent

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

Price target decreased to US$6.50

SomaLogic, Inc. Announces the Full-Scale Global Launch of the SomaLogic Certified Site Program

Consensus forecasts updated

High number of new and inexperienced directors

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2022

SomaLogic, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

SomaLogic appoints former Foundation Medicine chief as executive chair

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Consensus forecasts updated

SomaLogic Provides Revenue Guidance for the Full Year 2022

Price target decreased to US$7.75

Price target decreased to US$11.50

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

SomaLogic, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SomaLogic, Inc. Announces Resignation of Stephen Quake from the Board of Directors, Effective July 17, 2022

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Price target decreased to US$14.50

SomaLogic, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

SomaLogic, Inc., Annual General Meeting, Jun 06, 2022

SomaLogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Independent Director exercised options to buy US$275k worth of stock.

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

Now 24% undervalued after recent price drop

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

SomaLogic, Inc. to Report Q4, 2021 Results on Mar 29, 2022

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic Announces That the Company Will Begin Assaying Samples from the Multi-Ethnic Study of Atherosclerosis (Mesa) Study Beginning in the First Quarter of 2022

Oncohost Ltd. Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy

SomaLogic, Inc. Revises Revenue Guidance for the Year Ended December 31, 2021

High number of new and inexperienced directors

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Third quarter 2021 earnings released: US$0.55 loss per share

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Director recently bought US$160k worth of stock

No independent directors

Winst- en omzetgroeiprognoses